Literature DB >> 9222597

Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein.

C R Brown1, L Q Hong-Brown, J Biwersi, A S Verkman, W J Welch.   

Abstract

Mutations in the cystic fibrosis transmembrane conductance regulator protein (CFTR) often result in a failure of the protein to be properly processed at the level of the endoplasmic reticulum (ER) and subsequently transported to the plasma membrane. The folding defect associated with the most common CFTR mutation (delta F508) has been shown to be temperature sensitive. Incubation of cells expressing delta F508 CFTR at lower growth temperatures results in the proper processing of a portion of the mutant CFTR protein. Under these conditions, the mutant protein can move to the plasma membrane where it functions, similar to the wild-type protein, in mediating chloride transport. We set out to identify other methods, which like temperature treatment, would rescue the folding defect associated with the delta F508 CFTR mutation. Here we show that treatment of cells expressing the delta F508 mutant with a number of low molecular weight compounds, all known to stabilize proteins in their native conformation, results in the correct processing of the mutant CFTR protein and its deposition at the plasma membrane. Such compounds included the cellular osmolytes glycerol and trimethylamine N-oxide, as well as deuterated water. Treatment of the delta F508 CFTR-expressing cells with any one of these compounds, which we now refer to as 'chemical chaperones', restored the ability of the mutant cells to exhibit forskolin-dependent chloride transport, similar to that observed for the cells expressing the wild-type CFTR protein. We suggest that the use of 'chemical chaperones' may prove to be effective for the treatment of cystic fibrosis, as well as other genetic diseases whose underlying basis involves defective protein folding and/or a failure in normal protein trafficking events.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9222597      PMCID: PMC248464          DOI: 10.1379/1466-1268(1996)001<0117:ccctmp>2.3.co;2

Source DB:  PubMed          Journal:  Cell Stress Chaperones        ISSN: 1355-8145            Impact factor:   3.667


  123 in total

Review 1.  Antagonists to the rescue.

Authors:  W J Welch; M Howard
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 2.  Defective folding and rapid degradation of mutant proteins is a common disease mechanism in genetic disorders.

Authors:  N Gregersen; P Bross; M M Jørgensen; T J Corydon; B S Andresen
Journal:  J Inherit Metab Dis       Date:  2000-07       Impact factor: 4.982

3.  Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation.

Authors:  Ulla E Petäjä-Repo; Mireille Hogue; Suparna Bhalla; André Laperrière; Jean-Pierre Morello; Michel Bouvier
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

4.  In vivo action of the HRD ubiquitin ligase complex: mechanisms of endoplasmic reticulum quality control and sterol regulation.

Authors:  R G Gardner; A G Shearer; R Y Hampton
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

5.  Introducing Professor John H. Crowe, Anhydrobiosis and Biostabilization Section Editor.

Authors:  L E Hightower
Journal:  Cell Stress Chaperones       Date:  2000-07       Impact factor: 3.667

Review 6.  Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein.

Authors:  J R Riordan
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

7.  Structural cues involved in endoplasmic reticulum degradation of G85E and G91R mutant cystic fibrosis transmembrane conductance regulator.

Authors:  X Xiong; A Bragin; J H Widdicombe; J Cohn; W R Skach
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 8.  Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors.

Authors:  Alfredo Ulloa-Aguirre; P Michael Conn
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2011-01

Review 9.  New therapeutic approaches for cystic fibrosis lung disease.

Authors:  Jane C Davies
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

10.  Intracellular mislocalization of mutant podocin and correction by chemical chaperones.

Authors:  Teiko Ohashi; Keiko Uchida; Shinichi Uchida; Sei Sasaki; Hiroshi Nihei
Journal:  Histochem Cell Biol       Date:  2003-03-08       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.